COE Learning Network: Medications for Opioid Use Disorder Overview

April 5, 2023

The activity will allow the COE Healthcare team to understand treatment approaches and medications for OUD which will assist them in understanding a patient's candidacy for MOUD, misuse, diversion and how the treatments work.

Agenda:

  1. Introduction
  2. How an Opioid Use Disorder Develops
    1. Reward (Mesolimbic) Pathway
    2. Opioids act upon the brain reward pathway
    3. Opioid use changes brain chemistry over time
    4. Video
    5. OUD Diagnosis
  3. Treatment Approaches: Medications for Opioid Use Disorder (MOUD)
    1. Treatment Terminology
    2. Approaches to Treatment
    3. There is no one-size-fits-all approach to treatment.
    4. Detox is not treatment
    5. Goals of MOUD
    6. Effectiveness of MOUD
  4. FDA-Approved Medications for Treating OUD
    1. Opioid Agonists
    2. Opioid Antagonists
    3. Lock and Key
  5. MOUD- Medications
    1. Methadone Treatment
      1. Methadone Treatment Criteria
      2. Treatment Phases & Dosing
  6. Buprenorphine Treatment
    1. DATA-Waiver
    2. Formulations
    3. Buprenorphine/Naloxone
    4. Buprenorphine Treatment Phases
    5. Buprenorphine Induction
  7. Stabilization on MOUD
  8. Naltrexone Treatment
    1. Naltrexone Formulations
    2. Naloxone or Naltrexone Challenge
    3. Naltrexone Maintenance 
    4. Naltrexone Efficacy
  9. Determining Patient Candidacy for MOUD
    1. Assess Patient Candidacy
      1. Current Status
      2. History
      3. Treatment Options
    2. Potential Candidates: Methadone
    3. Potential Candidates: Buprenorphine
    4. Potential Candidates: Naltrexone
  10. Misuse and Diversion
    1. Definitions of misuse and diversion
    2. Buprenorphine Diversion
    3. Diversion & Misuse Reduction Strategies 
  11. Questions

Target Audience

Nurse

Physician

Social Worker

Learning Objectives

  • Describe how opioid use disorder (OUD) can develop as a result of changes in the brain.
  • Discuss the efficacy of medications for opioid use disorder (MOUD) for improving OUD treatment engagement, retention, and outcomes.
  • List the general treatment phases for treating OUD with MOUD.
  • List at least two factors that help determine which MOUD is best for a patient.
  • Describe strategies for monitoring treatment, including ensuring treatment adherence and minimizing misuse/diversion.

Additional Information

AttachmentSize
File Audience Disclosure slides (1.25)_19.pptx51.52 KB
File MOUD_Overview_Agenda_Objectives_Questions_References_.docx39.32 KB
PDF icon MOUD_for COEs_ V0.pdf1.17 MB
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  • 1.25 ANCC
    UPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
  • 1.25 ASWB
  • 1.25 Attendance
Course opens: 
04/05/2023
Course expires: 
07/31/2023
Event starts: 
04/05/2023 - 12:00pm EDT
Event ends: 
04/05/2023 - 1:30pm EDT
Add to calendar: 

The activity will allow the COE Healthcare team to understand treatment approaches and medications for OUD which will assist them in understanding a patient's candidacy for MOUD, misuse, diversion and how the treatments work.

Agenda:

  1. Introduction
  2. How an Opioid Use Disorder Develops
    1. Reward (Mesolimbic) Pathway
    2. Opioids act upon the brain reward pathway
    3. Opioid use changes brain chemistry over time
    4. Video
    5. OUD Diagnosis
  3. Treatment Approaches: Medications for Opioid Use Disorder (MOUD)
    1. Treatment Terminology
    2. Approaches to Treatment
    3. There is no one-size-fits-all approach to treatment.
    4. Detox is not treatment
    5. Goals of MOUD
    6. Effectiveness of MOUD
  4. FDA-Approved Medications for Treating OUD
    1. Opioid Agonists
    2. Opioid Antagonists
    3. Lock and Key
  5. MOUD- Medications
    1. Methadone Treatment
      1. Methadone Treatment Criteria
      2. Treatment Phases & Dosing
  6. Buprenorphine Treatment
    1. DATA-Waiver
    2. Formulations
    3. Buprenorphine/Naloxone
    4. Buprenorphine Treatment Phases
    5. Buprenorphine Induction
  7. Stabilization on MOUD
  8. Naltrexone Treatment
    1. Naltrexone Formulations
    2. Naloxone or Naltrexone Challenge
    3. Naltrexone Maintenance 
    4. Naltrexone Efficacy
  9. Determining Patient Candidacy for MOUD
    1. Assess Patient Candidacy
      1. Current Status
      2. History
      3. Treatment Options
    2. Potential Candidates: Methadone
    3. Potential Candidates: Buprenorphine
    4. Potential Candidates: Naltrexone
  10. Misuse and Diversion
    1. Definitions of misuse and diversion
    2. Buprenorphine Diversion
    3. Diversion & Misuse Reduction Strategies 
  11. Questions
Zoom Meeting
Pittsburgh, PA
United States

Elizabeth Schrage

In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and The Jewish Healthcare Foundation. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
As a Jointly Accredited Organization, University of Pittsburgh is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. University of Pittsburgh maintains responsibility for this course. Social workers completing this course receive 1.25 continuing education credits.

Physician (CME)
The University of Pittsburgh designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Social Work (ASWB)
The maximum number of hours awarded for this Continuing Social Work Education activity is 1.25 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  • 1.25 ANCC
    UPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
  • 1.25 ASWB
  • 1.25 Attendance
Please login or register to take this course.